Structure of TOR and its complex with KOG1

被引:71
作者
Adami, Alessandra
Garcia-Alvarez, Begona
Arias-Palomo, Ernesto
Barford, David
Llorca, Oscar
机构
[1] Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England
[2] CSIC, Ctr Invest Biol, Madrid 28040, Spain
关键词
D O I
10.1016/j.molcel.2007.05.040
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The target of rapamycin (TOR) is a large (281 kDa) conserved Ser/Thr protein kinase that functions as a central controller of cell growth. TOR assembles into two distinct multiprotein complexes: TORC1 and TORC2. A defining feature of TORC1 is the interaction of TOR with KOG1 (Raptor in mammals) and its sensitivity to a rapamycin-FKBP12 complex. Here, we have reconstructed in three dimensions the 25 A resolution structures of endogenous budding yeast TOR1 and a TOR-KOG1 complex, using electron microscopy. TOR features distinctive N-terminal HEAT repeats that form a curved tubular-shaped domain that associates with the C-terminal WD40 repeat domain of KOG1. The N terminus of KOG1 is in proximity to the TOR kinase domain, likely functioning to bring substrates into the vicinity of the catalytic region. A model is proposed for the molecular architecture of the TOR-KOG1 complex explaining its sensitivity to rapamycin.
引用
收藏
页码:509 / 516
页数:8
相关论文
共 27 条
[1]  
CHOI JP, 1996, EUROPEAN J POLITICAL, V12, P273, DOI DOI 10.1016/0176-2680(95)00017-8
[2]   The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability [J].
Dames, SA ;
Mulet, JM ;
Rathgeb-Szabo, K ;
Hall, MN ;
Grzesiek, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (21) :20558-20564
[3]   ADP_EM:: fast exhaustive multi-resolution docking for high-throughput coverage [J].
Garzon, Jose Ignacio ;
Kovacs, Julio ;
Abagyan, Ruben ;
Chacon, Pablo .
BIOINFORMATICS, 2007, 23 (04) :427-433
[4]   Topological characteristics of helical repeat proteins [J].
Groves, MR ;
Barford, D .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 1999, 9 (03) :383-389
[5]   An expanding role for mTOR in cancer [J].
Guertin, DA ;
Sabatini, DM .
TRENDS IN MOLECULAR MEDICINE, 2005, 11 (08) :353-361
[6]   Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action [J].
Hara, K ;
Maruki, Y ;
Long, XM ;
Yoshino, K ;
Oshiro, N ;
Hidayat, S ;
Tokunaga, C ;
Avruch, J ;
Yonezawa, K .
CELL, 2002, 110 (02) :177-189
[7]   TARGETS FOR CELL-CYCLE ARREST BY THE IMMUNOSUPPRESSANT RAPAMYCIN IN YEAST [J].
HEITMAN, J ;
MOVVA, NR ;
HALL, MN .
SCIENCE, 1991, 253 (5022) :905-909
[8]   TUMOR-NECROSIS-FACTOR RECEPTOR-MEDIATED SIGNALING PATHWAYS [J].
HELLER, RA ;
KRONKE, M .
JOURNAL OF CELL BIOLOGY, 1994, 126 (01) :5-9
[9]   Complexity of the TOR signaling network [J].
Inoki, K ;
Guan, KL .
TRENDS IN CELL BIOLOGY, 2006, 16 (04) :206-212
[10]   Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive [J].
Jacinto, E ;
Loewith, R ;
Schmidt, A ;
Lin, S ;
Rüegg, MA ;
Hall, A ;
Hall, MN .
NATURE CELL BIOLOGY, 2004, 6 (11) :1122-U30